These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9764610)

  • 21. Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor.
    Makrides SC; Nygren PA; Andrews B; Ford PJ; Evans KS; Hayman EG; Adari H; Uhlén M; Toth CA
    J Pharmacol Exp Ther; 1996 Apr; 277(1):534-42. PubMed ID: 8613964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble complement receptor 1 inhibits both complement and granulocyte activation during ex vivo hemodialysis.
    Himmelfarb J; McMonagle E; Holbrook D; Toth C
    J Lab Clin Med; 1995 Oct; 126(4):392-400. PubMed ID: 7561449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced complement receptor 1 (CR1, CD35) transcription in systemic lupus erythematosus.
    Arora V; Verma J; Dutta R; Marwah V; Kumar A; Das N
    Mol Immunol; 2004 Jun; 41(4):449-56. PubMed ID: 15163541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble complement receptor type 1 prevents human complement-mediated damage of the rabbit isolated heart.
    Homeister JW; Satoh PS; Kilgore KS; Lucchesi BR
    J Immunol; 1993 Feb; 150(3):1055-64. PubMed ID: 8423331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Plasma prekallikrein in chronic liver diseases].
    Ciechanowicz A; Miks B; Kawiak J; Ciechanowski K; Ryszkiewicz D; Długosz A; Syczewska-Wawrzynowicz M; Marzecka J; Czekalski S
    Pol Arch Med Wewn; 1995 Nov; 94(5):395-401. PubMed ID: 8833936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma.
    Hsu PI; Chow NH; Lai KH; Yang HB; Chan SH; Lin XZ; Cheng JS; Huang JS; Ger LP; Huang SM; Yen MY; Yang YF
    Anticancer Res; 1997; 17(4A):2803-9. PubMed ID: 9252719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of an ELISA for the quantitation of human complement receptor 1.
    Sivasankar B; Raju KR; Ayub S; Srivastava LM; Das N
    J Immunoassay Immunochem; 2001; 22(3):289-97. PubMed ID: 11506278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating intercellular adhesion molecule-1 in chronic liver disease and hepatocellular carcinoma.
    Huang YS; Wu JC; Chan CY; Chao Y; Chang FY; Lee SD
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Aug; 62(8):487-95. PubMed ID: 10462824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elastase and metalloproteinase activities regulate soluble complement receptor 1 release.
    Sadallah S; Hess C; Miot S; Spertini O; Lutz H; Schifferli JA
    Eur J Immunol; 1999 Nov; 29(11):3754-61. PubMed ID: 10556832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study.
    Mazziotti G; Sorvillo F; Morisco F; Carbone A; Rotondi M; Stornaiuolo G; Precone DF; Cioffi M; Gaeta GB; Caporaso N; Carella C
    Cancer; 2002 Dec; 95(12):2539-45. PubMed ID: 12467068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of serum percent trisialotransferrin as potential predictive biomarker of hepatocellular dedifferentiation in chronic liver disease.
    Gressner OA; Jafari S; Erkens M; Gao C; Stanzel S; Gressner AM
    Clin Chim Acta; 2009 May; 403(1-2):188-93. PubMed ID: 19281805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of serum adiponectin in Egyptian patients with HCV-related cirrhosis and hepatocellular carcinoma.
    Hamdy K; Al Swaff R; Hussein HA; Gamal M
    J Endocrinol Invest; 2015 Nov; 38(11):1225-31. PubMed ID: 26359143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction of the plasmid, expression by Chinese hamster ovary cell, purification and characterization of the first three short consensus repeat modules of human complement receptor type 1.
    Yamaguchi A; Takagawa H; Iwakaji H; Miyagawa S; Wang PC; Ishii N
    J Biochem; 2009 Apr; 145(4):533-42. PubMed ID: 19218189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular endothelial growth factor level in chronic liver diseases.
    Makhlouf MM; Awad A; Zakhari MM; Fouad M; Saleh WA
    J Egypt Soc Parasitol; 2002 Dec; 32(3):907-21. PubMed ID: 12512823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts.
    Koruk M; Onuk MD; Akçay F; Savas MC
    Hepatogastroenterology; 2002; 49(48):1645-8. PubMed ID: 12397754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum miRNA-27a and miRNA-18b as potential predictive biomarkers of hepatitis C virus-associated hepatocellular carcinoma.
    Rashad NM; El-Shal AS; Shalaby SM; Mohamed SY
    Mol Cell Biochem; 2018 Oct; 447(1-2):125-136. PubMed ID: 29455432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum alpha-fetoprotein levels in patients with acute and chronic liver disease. Relation to hepatocellular regeneration and development of primary liver cell carcinoma.
    Eleftheriou N; Heathcote J; Thomas HC; Sherlock S
    J Clin Pathol; 1977 Aug; 30(8):704-8. PubMed ID: 74380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
    Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
    PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensity of inflammatory damage and serum lipid peroxide concentrations in liver disease.
    Fabris C; Pirisi M; Panozzo MP; Soardo G; Toniutto P; Hocza V; Bartoli E
    J Clin Pathol; 1993 Apr; 46(4):364-7. PubMed ID: 8388408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium.
    Weisman HF; Bartow T; Leppo MK; Boyle MP; Marsh HC; Carson GR; Roux KH; Weisfeldt ML; Fearon DT
    Trans Assoc Am Physicians; 1990; 103():64-72. PubMed ID: 2132543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.